† VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies
Title:
† VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies
Author:
Flight, Patrick Rohde, Ellen Lee, Richard Mazzola, Anne Marie Platt, Colin Mizoguchi, Taiji Pendino, Kim Chadwick, Alexandra Khera, Amit Vafai, Scott Kathiresan, Sekar Lister, Troy Biedenkapp, Joseph